Inmune Bio Completes Early INKmune Trial in Advanced Prostate Cancer: What Investors Should Watch Next

Inmune Bio (INMB) announced an update on their ongoing clinical study.

Inmune Bio, Inc. is running a study called “An Open-label, Phase I/IIa Dose Escalation and Expansion Study to Determine the Safety and Clinical Activity of an Immune Priming Cell Therapy (INKmune) in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC).” The goal is to test safety and early signs of benefit in men with advanced prostate cancer that no longer responds to hormone therapy.

The treatment is INKmune, a cell-based cancer therapy given by intravenous infusion. It is designed to prime a patient’s own natural killer cells so they can better find and attack tumor cells.

This is an interventional trial where all patients receive INKmune, but at different dose levels over time. The study is open-label, meaning both doctors and patients know the dose, and the main aim is to find a safe dose and see early signals of treatment effect.

Patients are enrolled into three sequential groups that receive rising doses, followed by an expansion phase at selected dose levels. The trial is non-randomized and focuses on treatment rather than comparison to a control group, making it a typical early-stage oncology design.

The study was first submitted to the registry on Aug. 7, 2023, marking the formal start of public tracking. The latest update was filed on Feb. 25, 2026, signaling that trial records and status have been recently refreshed.

The trial is listed as completed, which suggests patient dosing and follow-up are done. Primary completion and final completion dates are important for timing data releases, and investors should watch for when top-line safety and activity data are disclosed.

For INMB, a completed Phase I/IIa in metastatic castration-resistant prostate cancer is a key de-risking step. Clean safety data and any signal of tumor control could support a higher valuation, easier capital raises, and stronger negotiating power with partners.

However, this remains a very early-stage program, and any move in INMB stock will depend on the actual readout, not just the update status. Competitors in mCRPC, including large-cap pharma and other cell therapy developers, set a high bar, so investors should be ready for both upside surprise and clinical risk.

With the study now completed and records recently updated, the INKmune program remains in active development, and further details are available on the ClinicalTrials portal.

To learn more about INMB’s potential, visit the Inmune Bio drug pipeline page.